Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, Morganna, Kim, Youngchul, Cronin, Heather, Richards, Allison, Gibney, Geoffrey, Weber, Jeffrey S.·2016·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-15-1136

Cited by (860)

Items 701–800 of 860

Radiotherapy May Exacerbated Anti-Programmed Cell Death 1 Treatment Induced Vitiligo: A Case Report
Chengqian Chen, Qihang Chang, Bo Wang, Yaqi Wang, Zhen Zhang, Xiuli Wang · 2023 · Skin Health and Disease
Novel thyroid-specific autoantibodies in patients with immune-related adverse events involving the thyroid gland
Ichiro Yamauchi, Akihiro Yasoda, Takuro Hakata, Takafumi Yamashita, Keisho Hirota, Yohei Ueda, Toshihito Fujii, Daisuke Taura, Masakatsu Sone, Nobuya Inagaki · 2024 · Thyroid Science
Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, Hiroshi Masumoto, Yoko Takahashi, Yasuhisa Hasegawa, Koji Tamura · 2024 · Journal of Pharmaceutical Health Care and Sciences
Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review
Danielle H. Tran, Ryan P. Shanley, Alessio Giubellino, Peter H. Tang, Dara D. Koozekanani, Jianling Yuan, Kathryn E. Dusenbery, Evidio Domingo‐Musibay · 2024 · Frontiers in Oncology
Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire
Reda El Hazzaz, Maria Kfoury, Pernelle Lavaud, Aurélien Marabelle, Stéphane Champiat, Nawfel Mellas, Benjamin Besse, Christophe Massard, Arthur Géraud · 2021 · Bulletin du Cancer
Arzneimittelexantheme unter modernen zielgerichteten Therapien – Immuncheckpoint‐ und EGFR‐Inhibitoren
Isabella Pospischil, Wolfram Hoetzenecker · 2021 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
A good surgical field for para-aortic nodal dissection in gastric cancer by the Cattell-Braasch maneuver
Masayuki Akita, Eri Maeda, Ryo Ishida, Tatsuya Morikawa, Tohru Nishimura, Koichiro Abe, Akihito Kozuki, Tomohiro Tanaka, Kunihiko Kaneda · 2022 · Langenbeck s Archives of Surgery
Problematic Landmark Analysis Has Led to a Problematic Conclusion
Fei Liang, Sheng Zhang, Ji Ye Zhu · 2017 · Journal of Clinical Oncology
Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
Ikko Tomisaki · 2019 · IJU Case Reports
Liver dysfunction of Atezolizumab + Bevacizumab ‐a matter of life or death−
Shuntaro Obi, Masao Omata · 2021 · Liver International
Safety and Efficacy of Immune Checkpoint Inhibitors in Advanced Cancer patients with Autoimmune Disease: a Meta-Analysis
Qi Cai, Gengwei Huo, Fuyi Zhu, Ping Yue, Dongqi Yuan, Peng Chen · 2022 · Research Square
Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects
Aysın Tulunay Virlan, Giacomo Cafaro, Flavia Sunzini, Yannick Degboé, Maria Christodoulou · 2024 · Frontiers in Oncology
Vitiligo in a patient with metastatic melanoma receiving human immunoglobulin G4 monoclonal antibodynivolumab treatment
Şule Gökşin, Serkan Değirmencioğlu · 2022 · TURKDERM
[Translated article] Adverse Dermatologic Reactions in Patients Treated With Immune Checkpoint Inhibitors
Rafael Fayos‐Gregori, Carolina Labrandero Hoyos, Rodrigo Peñuelas Leal, V. Alegre de Miquel · 2023 · Actas Dermo-Sifiliográficas
Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
Ting Zhang, Sicheng Du, Ying Zhang, Rongrui Liu, Juan Li, Chuanhua Zhao, Jianming Xu · 2025 · Cancer Medicine
Targeted therapies induced depigmentation: a review
Zhaoyang Wang, Meng Wang, Tianyu Wang, Xiaoxiao Yan, Zhenhua Yue, Yonghu Sun · 2025 · Frontiers in Immunology
Soluble IL‐2 receptor levels support diagnosis of sarcoidosis‐like reaction in melanoma patients on immunotherapy – a diagnostic algorithm based on a single center retrospective study
Philipp Gussek, Julia Mentzel, Maxime Ablefoni, Mirjana Ziemer · 2025 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
Association between immune-related adverse events and recurrence dynamics under adjuvant anti–PD-1 therapy in resected melanoma
Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel, Salih Tünbekici, Fatma Pınar Açar, Banu Yaman, Burçak Karaca · 2025 · Frontiers in Oncology
Analysis of anticancer drug associated adverse reactions in depressive patients from vigibase
B. Chrétien, C. Dolladille, Kazuki Nishida, B. Aleksic, Joachim Alexandre, J. L'Orphelin · 2025 · Scientific Reports
Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer
Özge Büyükahısha, Abdullah Özçelik, Deniz Bayçelebi, Asena Cakir, Bülent Çetin · 2026 · Frontiers in Oncology
Engineering tumor-specific interferon-alpha-Nivolumab pro-immunocytokine for enhanced melanoma immunotherapy
Shi-Wei Chao, Bo‐Cheng Huang, Shih-Ting Hong, Kai‐Wen Ho, Yen-Tseng Wang, Yu-Ting Huang, Chia-Tse Li, Shan-Jou Chen, Hong-Ren Wang, Yi-Jung Huang et al. · 2026 · International Journal of Biological Macromolecules
Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study
Takahito Sugase, Takashi Kanemura, Norihiro Matsuura, Kei Yamamoto, Yuki Ushimaru, Yasunori Masuike, Yoshitomo Yanagimoto, Kazuyoshi Yamamoto, Yoshihiro Sakano, Ryota Mori et al. · 2026 · Annals of Surgical Oncology
Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
Yohei Iimura, Junichi Higuchi, Akimitsu Maeda, Kazuhiro Shimomura, Hirotoshi Iihara, Hironori Fujii, Takuya Iwamoto, Yoshitaka Saito, Hisanaga Nomura, Keiko Komori et al. · 2026 · International Journal of Clinical Oncology
Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions
Aysima Önal, Furkan Ayaz, Esra Aydemir · 2026 · Molecular Biology Reports
Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report
Yinglei Deng, Dahua Mao, Shaogang Zhang, Jing Wang · 2026 · Frontiers in Oncology
Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1
Aurore Vozy, Clélia Coutzac · 2016 · ONCOLOGIE
Severe infusion reaction caused by nivolumab immunotherapy, followed by remarkable response in an elderly patient with advanced mucosal melanoma
Koji Adachi, Yuichi Yoshida, Yuko Ehara, Reiko Tsutsumi, Osamu Yamamoto · 2016 · Australasian Journal of Dermatology
Immune-Related Adverse Toxicities and Clinical Management
Michael Constantin Kirchberger, Lucie Heinzerling · 2018 · Springer eBooks
Patterns of immunotherapy use and management of toxicities in regional and tertiary settings
Brett Hamilton, Kay Xu, Florian Honeyball, Bavanthi Balakrishnar, Rob Zielinski · 2019 · Internal Medicine Journal
Clinical analysis for head and neck cancer cases treated with nivolumab in Osaka International Cancer Institute
Tomoyuki Otsuka, Takayuki Kimura, Ryosuke Koike, Hironori Cho, Shinji Otozai, Tadashi Yoshii, Toshinari Yagi, Takashi Fujii · 2019 · Toukeibu Gan
Acute-onset type 1 diabetes mellitus developing after administration of pembrolizumab: a case report
Akimasa Sakamoto, Naotake Funamizu, Miku Iwata, Tomoyuki Nagaoka, Kei Tamura, Katsunori Sakamoto, Akihiro Takai, Kohei Ogawa, Yasutsugu Takada · 2021 · Suizo
Nivolumab
Anand Rotte, Madhuri Bhandaru · 2016 · Springer eBooks
Reacciones adversas dermatológicas en pacientes con terapia dirigida contra inhibidores de la respuesta inmune
Rafael Fayos‐Gregori, Carolina Labrandero Hoyos, Rodrigo Peñuelas Leal, V. Alegre de Miquel · 2022 · Actas Dermo-Sifiliográficas
Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients
Adi Horesh, Rena M. Pollack, Hovav Nechushtan, Rivka Dresner–Pollak, Tzahi Neuman · 2023 · Pathology & Oncology Research
High risks adverse events associated with usage of aspirin in chronic obstructive pulmonary disease
Xiaohua Li, Bin Dai, Qingbing Han, Yanqiu Wu, Bi Ran, Tao Wang, Fuqiang Wen, Jun Chen · 2023 · Expert Review of Respiratory Medicine
Age-related outcomes in MSI/dMMR gastrointestinal cancers treated by immune checkpoint inhibitors and toxicity’s impact on efficacy: an immunoMSI cohort study
Léah Mailly-Giacchetti, Raphaël Colle, Thomas Samaille, Daniel Lopez-Trabada Ataz, Lilith Faucheux, Alex Duval, Thierry André, Romain Cohen · 2024 · ESMO Gastrointestinal Oncology
A Curious Case of Diabetic Ketoacidosis Secondary to Avelumab
Mafalda Costa, Helena Magalhães · 2024 · Cureus
Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report
Shadi Chamseddine, Michael Brian LaPelusa, Kristen Carter, Van Du Nguyen, Yehia Ibrahim Mohamed, Yara Sakr, Cristhiam Mauricio Rojas Hernandez, Rikita I. Hatia, Manal M. Hassan, John A. Goss et al. · 2024 · Journal of Gastrointestinal Oncology
Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore
Agnes Yeok-Loo Lim, Jason Yongsheng Chan, Choon Chiat Oh · 2024 · Diagnostics
Adverse Events as a Function of Biological Sex in a Multicenter Clinical Trial of Melanoma Vaccines
Catherine E. Lyons, Ruyun Jin, Aaron D Smith, Hong Zhu, Craig Lee Slingluff · 2024 · Cancers
Remarkable Antitumor Effects and Serious Multiple Immune‐Related Adverse Events in Malignant Pleural Mesothelioma: Two Case Reports
Koharu Harada, H. Irie, Akifumi Mitsuishi, Takahiro Fukui, Nao Takada, Ryosuke Nagaoka, Yohei Funatsu, Hidefumi Koh · 2025 · Case Reports in Oncological Medicine
Postoperative Development of Polymyalgia Rheumatica Due to Nivolumab Administration in a Patient with Recurrent Anorectal Malignant Melanoma
Tomonari Suetsugu, Nobuhisa Matsuhashi, Takao Takahashi, Toshiyuki Tanahashi, Satoshi� Matsui, Hisashi Imai, Yoshihiro Tanaka, Kazuya Yamaguchi, Tatsuhiko Miyazaki, Kazuhiro Yoshida · 2019 · 日本消化器外科学会雑誌
転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス
清田尚臣 · 2019 · Nippon Jibiinkoka Gakkai Kaiho
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
Víctor Sapena, Massimo Alberto Iavarone, Loreto Boix, F. Facchetti, Maria Guarino, Marco Sanduzzi‐Zamparelli, Alessandro Granito, Esther Samper, Mario Scartozzi, Josep Corominas et al. · 2022 · World Journal of Hepatology
Dermatology (Skin)
Alexandria M. Brown, Wylie M. Masterson, Anisha B. Patel · 2022 · Springer eBooks
Reply to “Guarantee‐time bias in studies on the relationship between immune‐related adverse events and antitumor activity”
Corey Christian Foster, Tanguy Y. Seiwert · 2022 · Cancer
TNF blockade with certolizumab improves the efficacy of anti-PD-1 and anti-CTLA-4 combination therapy for melanoma
Tania Margarido Pereira, Mathieu Virazels, Benjamin Jung, Thomas Filleron, Laure Badier, Étienne Leclercq, Stéphanie Brayer, Matthieu Genais, Laura Leroy, Amélie Lusque et al. · 2026 · medRxiv
Checkpoint Inhibitor-Associated Autoimmunity: What a Rheumatologist Needs to Know.
Nilasha Ghosh, Anne R. Bass · 2022 · PubMed
Reply to F. Liang et al
Jeffrey S. Weber, Joel Jiang · 2017 · Journal of Clinical Oncology
REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION
Derek R. Clements · 2018 · DalSpace (Dalhousie University)
Immunobiology of the Melanoma Microenvironment
Yutaka Kawakami, Adam I. Riker · 2018 · Springer eBooks
Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
Naomi Kiyota · 2018 · Journal of Japanese Society of Oral Oncology
Immune check point inhibitors for head and neck cancer
Naomi Kiyota · 2018 · Toukeibu Gan
Biomarkers for gastrointestinal immunotherapy-related adverse events
Dmitrii Shek · 2018 · Frontiers in Drug Chemistry and Clinical Research
Cutaneous Adverse Events of Systemic Melanoma Treatments
Christian Menzer, Steven T. Chen, Gregory S. Phillips, Mario E. Lacouture · 2019 · Springer eBooks
Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen
Kristina Zdanytė, Ludwig Kiesel · 2019 · Gynäkologische Endokrinologie
Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies
Katia Boniface, Julien Sénéschal · 2019 · Springer eBooks
Dermatological Complications of Systemic Therapies for Melanoma
Egle Ramelyte, Reinhard Dummer, Cristina Libenciuc, Gregory S. Phillips, Mario E. Lacouture, Caroline Robert · 2019 · Springer eBooks
A case of malignant melanoma with repeated development of drug eruption during immune checkpoint inhibitor therapy
Nagisa FUJIMORI, Yuka Kobayashi, Sayaka Togo, Akari KAGANOI, Kentaro Ozawa, Taiki Isei · 2019 · Skin Cancer
Drug Toxicity, Approach to Cancer as a Systemic Disease, and Imaging Modality-Specific Considerations
Hyesun Park, Mizuki Nishino · 2020 · Medical radiology
A Case of Colon Perforation during the Treatment with an Immune Checkpoint Inhibitor
Wakana Chikaishi, Nobuhisa Matsuhashi, Takao Takahashi, Yoshihiro Tanaka, Kazuya Yamaguchi, Kazuhiro Yoshida · 2019 · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
Bullous pemphigoid developed during administration of Pembrolizumab : A case report
Kosuke SATAKE, Manabu Suwa, Toshikazu Omodaka, Yuki Sato, Tomomi Miyake, Atsuhito Ushiki, Yukiko Kiniwa, Ryuhei Okuyama · 2020 · Skin Cancer
A case of simultaneous double cancer of oral malignant melanoma and lung adenocarcinoma with nivolumab-induced destructive thyroiditis
Tomohiro TAKAYAMA, Kaoru Murakami, Chikashi Minemura, Ryota YOSHIDOME, Koji Yamamura, Hidetaka Yokoe · 2020 · Japanese Journal of Oral & Maxillofacial Surgery
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
Gerard Alain Milano, Federico Innocenti, Joseph Ciccolini · 2020 · Translational Oncology
Nivolumab 投与を行った再発・転移頭頸部扁平上皮癌症例の検討
中島紘一郎, 安松隆治, 高良佳江, 古後龍之介, 若崎高裕, 中川尚志 · 2019 · 耳鼻と臨床
Immunotherapy in Cancer: Immune Checkpoint Inhibitors; Changing Oncology Treatment Paradigm
Safiuddin Shoeb Syed · 2020 · Springer eBooks
Oral Lichenoid Lesions Due to Nivolumab: A Case Report and Review of the Literature
Tomohisa Nakamura, Yoshinori Jinbu, Yasuyuki Shibuya, Toshio Demitsu, Yoshiyuki Mori · 2020 · Journal of Japanese Society of Oral Medicine
Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management
Carolina Lopes, S Morgado, Ana I. Plácido, Fátima Roque, Manuel Morgado · 2021 · SN Comprehensive Clinical Medicine
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritis
Laura C. Cappelli, Clifton O. Bingham · 2021 · Springer eBooks
Pulmonary Toxicities of Immunotherapy
Pradnya Dinkar Patil, Tanmay S. Panchabhai · 2020 · Elsevier eBooks
Dermatologic Toxicities of Immunotherapy
Pradnya Dinkar Patil, Vamsidhar Velcheti · 2020 · Elsevier eBooks
The influence of monoclonal antibodies for cancer treatment on the endocrine system
Kamil Dyrka, Daria Witasik, Agata Czarnywojtek, Katarzyna Łącka · 2021 · Postępy Higieny i Medycyny Doświadczalnej
Absolute Eosinophil Count May be One of the Most Optimal Peripheral Blood Markers to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors.
Yan Ma, Xiao Ma, Jingting Wang, Shanshan Wu, Jing Wang, Bangwei Cao · 2021 · Research Square
Association Between Immune-Related Hypothyroidism and Survival Outcomes in Patients with Head and Neck Cancer Treated with Nivolumab
Kojiro Hata, Keiichi Sasaki, Hiroyuki Watanabe, Munehiko Ikeda, Toshikazu Tsuji, Shigeru Ishida, Mio Ikebe, Ayako Kumagai, Nana Ozawa, Ryosuke Matsukane et al. · 2021 · Research Square
Questions pratiques en immunothérapie dans le cancer bronchique non à petites cellules : dose, durée, rythme de traitement, réintroduction
Audrey Rabeau, J. Lavesque, C. Joseph, Alexis Benjamin Cortot, Julien Mazières · 2021 · Revue des Maladies Respiratoires Actualités
Vitiligo as durvalumab's immune-related adverse event in lung cancer
Jacobo Rogado, Diego Buendía‐Castaño, Soledad R. Alonso-García · 2021 · Medicina Clínica
Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale
Leslie Adda, Benjamin Batteux, Zuzana Saidak, Claire Poulet, Jean‐Philippe Arnault, Bruno Chauffert, Alice Séjourné · 2021 · Revue du Rhumatisme
Successful Conversion Surgery Following Bullous Pemphigoid after Nivolumab for Advanced Gastric Cancer
Eri Maeda, Masayuki Akita, Tohru Nishimura, Kouichirou Abe, Akihito Kozuki, Kunio Yokoyama, Tomohiro Tanaka, Shinji Kishi, Chihiro Ichikawa, Yukihiro Imai et al. · 2021 · 日本消化器外科学会雑誌
A case of bullous pemphigoid in the oral cavity after treatment with nivolumab
Yoshitomo Nishio, Akifumi Furuhashi, Tomio Hayashi, Kunihiro Ito, Takayuki Ono, Yoshiaki Kazaoka · 2021 · Japanese Journal of Oral & Maxillofacial Surgery
Immune Checkpoint Inhibitor Induced Vitiligo in Non-Melanoma Patients: Characterization and Management
Jonathan Lo, Hannah L. Hanania, Monika F. Keiser, Anisha B. Patel · 2022 · Research Square
Cutaneous Adverse Events of Systemic Melanoma Treatments
Christian Menzer, Steven T. Chen, Gregory S. Phillips, Mario E. Lacouture · 2019 · Springer eBooks
Melanoma Immunotherapy
Gregory A. Daniels · 2017 · Current cancer research
Dermatological Complications of Systemic Therapies for Melanoma
Egle Ramelyte, Reinhard Dummer, Cristina Libenciuc, Gregory S. Phillips, Mario E. Lacouture, Caroline Robert · 2020 · Springer eBooks
A single－institute experience with immune－related adverse events caused by immune checkpoint inhibitors
Yoshinori Muto, Nobuhiro DEGUCHI, Takashi Inozume, Hiroshi Mitsui, Youichi Ogawa, Takehiro ONUMA, Shinji Shimada, Tatsuyoshi Kawamura · 2021 · Skin Cancer
Vitiligo as durvalumab's immune-related adverse event in lung cancer
Jacobo Rogado, Diego Buendía‐Castaño, Soledad R. Alonso-García · 2022 · Medicina Clínica (English Edition)
Faculty Opinions recommendation of The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Christian Münz, Obinna Chijioke · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
頭頸部がんにおける免疫チェックポイント阻害薬の適応と実際
清田尚臣 · 2018 · Nippon Jibiinkoka Gakkai Kaiho
Safety and Efficacy of Immune Checkpoint Inhibitors in Advanced Cancer patients with Autoimmune Disease: a Meta-Analysis
Qi Cai, Gengwei Huo, Fuyi Zhu, Ping Yue, Dongqi Yuan, Peng Chen · 2022 · Research Square
Cutaneous Toxic Effects in tumor patients treated with Programmed Cell Death Protein-1 checkpoint inhibitors and/or Programmed Death-Ligand 1 checkpoint inhibitors and its association with survival: a systematic review and meta-analysis
Fangmin Zhao, Junjing Zhu, Tianyu Shao, Shuyi Chen, Gaochenxi Zhang, Qijin Shu · 2022 · Research Square
Elevated eosinophils as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma： a multicenter cohort study Eosinophil could be biomarkers for irAE
Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Nayuka Matsuyama, Yasuhito Sue et al. · 2022 · Research Square
Elevated eosinophils as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Nami Tomiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Nayuka Matsuyama, Yasuhito Sue et al. · 2022 · Research Square
Immune Checkpoint Inhibitor Induced Vitiligo in Non-Melanoma Patients: Characterization and Management
Jonathan W. Lo, Hannah L. Hanania, Monika F. Keiser, Anisha B. Patel · 2022 · Research Square
Nanovesicles for targeting autoimmune diseases
Rahat Andleeb, Muhammad Umar Ijaz, Asma Ashraf, Rida Rafi, Derya Karataş Yeni, Shabana Naz, Tayyaba Ali, Muhammad Asad Sajid · 2022 · Elsevier eBooks
Safety and Efficacy of Immune Checkpoint Inhibitors in Advanced Cancer patients with Autoimmune Disease: a Meta-Analysis
Peng Chen, Qi Cai, Gengwei Huo, Fuyi Zhu, Ping Yue, Dongqi Yuan · 2022 · Research Square
ANALYSIS OF THE ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA
Akihito Hashizume, Ryo Yamashita, Hideo Shinsaka, Masafumi Nakamura, Masato Matsuzaki, Masashi Niwakawa · 2021 · The Japanese Journal of Urology
Cutaneous Reactions to Oncologic Immunotherapy
Rachel Choi, Jonathan Scott Leventhal · 2022 · Updates in clinical dermatology
Effects of Nivolumab for the Head and Neck Carcinoma Patients
Katsunori Tanaka, Hiroyuki Maeda, Hidetoshi Kinjo, Shinya Agena, Hitoshi Hirakawa, Mikio Suzuki · 2022 · Practica Oto-Rhino-Laryngologica
Pulmonary Side Effects of Immunotherapy
Cihan Erol, Mehmet Alı Nahıt Şendur · 2023 · Springer eBooks
Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
Maria Grigoriou, Aggelos Banos, Aikaterini Hatzioannou, Andreas Kloetgen, Panagiotis Kouzis, Despoina Aggouraki, Roubini Zakopoulou, Giorgos Bamias, Eva N. Kassi, Dimitriοs Mavroudis et al. · 2023
Data from Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
Yael Eshet, Erez N. Baruch, Ronnie Shapira‐Frommer, Yael Steinberg‐Silman, Teodor Kuznetsov, Guy Ben‐Betzalel, Sameh Daher, Iris Gluck, Nethanel Asher, Sara Apter et al. · 2023